A Novel Strategy for the Convergent Synthesis of 1,3,5,...-Polyols: Enone Formation, Asymmetric Dihydroxylation, Reductive Cleavage, Hydride Addition

Karsten Körber, Philippe Risch, Reinhard Brückner*

Institut für Organische Chemie und Biochemie, Albert-Ludwigs-Universität Freiburg, Albertstr. 21, 79104 Freiburg, Germany Fax +49(761)2036100; E-mail: reinhard.brueckner@organik.chemie.uni-freiburg.de *Received 27 September 2005*

Abstract: Asymmetric dihydroxylation of α , β -unsaturated ketones provided α , β -dihydroxyketones with up to 100% ee. The C^{*a*}–O bond of these intermediates or their bis-TMS ethers, acetonides, phenylborates or orthoformiates was cleaved with SmI₂, affording β -hydroxyketones. The latter can be reduced to furnish *syn-* or *anti*-configured 1,3-diols of any desired configuration.

Key words: defunctionalization, 1,3-diol, Horner–Wadsworth– Emmons olefination, β -hydroxy ketones, samarium iodide, α , β -unsaturated ketones

1,3,5,...-Polyols without substituents at C^2 , C^4 , C^6 ,... are the core structural feature of the polyol/polyene macrolide antibiotics **1** (Scheme 1).¹ This family of compounds comprises more than 200 members. Those representatives of which not only the constitution but also the configuration is known have received considerable attention in the synthetic community.^{1,2} This is due to a desire of developing methodology for making such molecules in a stereocontrolled manner. In a longer perspective, the synthetic interest in polyol/polyene antibiotics **1** is motivated by the wish to understand the correlation (if any) between their 3D structure and their biological activity.

Preferably, extended stretches 2 of 1,3,5,...-polyols should emerge from a convergent strategy (Scheme 1). In state-of-the-art syntheses of 2,4,6,...-substituted 1,3,5,...polyol building blocks, such convergency is typically due to the inclusion of β -hydroxyketone intermediates and their construction through 'complex aldol additions'.³ β -Hydroxyketone intermediates 3 have been used en route to extended polyols 2, too; they arose from the aldol addition of enolates 5 to aldehydes $4^{2e,g,4}$ or from a different approach.⁵ Here we communicate a novel way of making polyols 2 via β -hydroxyketones 3: by the α -defunctionalization of α,β -dihydroxyketones 6. The latter stem from the asymmetric dihydroxylation⁶ ('AD') of enones 7, which, in turn, result from Horner-Wadsworth-Emmons olefinations of aldehydes 8 or from analogous Wittig reactions.

We started with the AD of the α , β -unsaturated ketone **9a** (Scheme 2). Trying to accelerate conversion, we utilized the so-called improved⁷ rather than standard procedure,⁸ i. e., employed 1 mol% K₂OsO₂(OH)₄ instead of 0.2 mol%

SYNLETT 2005, No. 19, pp 2905–2910 Advanced online publication: 04.11.2005 DOI: 10.1055/s-2005-921915; Art ID: G29405ST © Georg Thieme Verlag Stuttgart · New York



Scheme 1 Convergent approaches to 'skipped polyol' building blocks 2 of polyol/polyene macrolide antibiotics 1 via type-3 β -hydroxyketone intermediates.

and 5 mol% (DHQD)₂PHAL instead of 1 mol%. Even so this reaction required 2.5 days at 0 °C to furnish diol αS , βR -**10a**⁹ in 89% yield and with 100% ee¹⁰ (after extractive work up and purification by flash chromatography on silica gel¹¹). Hence, the reaction rate was somewhat lower and stereocontrol somewhat better than in the not too many known ADs of α , β -unsaturated ketones.^{12–15}



Scheme 2 SmI₂-mediated α-reductions of a model α,β-dihydroxyketone and derivatives thereof. *Reagents and conditions*: a) K₂OsO₂(OH)₄ (1 mol%), (DHQD)₂PHAL (5 mol%), K₃Fe(CN)₆ (3.0 equiv), NaHCO₃ (3.0 equiv), K₂CO₃ (3.0 equiv), *t*-BuOH–H₂O 1:1 (v:v), 0 °C, 60 h; b) SmI₂ (2.1 equiv), THF, -78 °C, addition of substrate in THF–MeOH 2:1 (v:v), 50 min; -78 °C to r.t., 30 min; c) pyridinium *p*-toluenesulfonate (10 mol%), 2,2-dimethoxypropane, r.t., 24 h; PTSA (3 mol%), 22 h; d) phenylboronic acid (1.1 equiv), CH₂Cl₂, r.t., 24 h; e) SOCl₂ (1.1 equiv), DMF (5 mol%), CH₂Cl₂, 0 °C, 1 h; then r.t., 4 h; f) trimethyl orthoformiate (1.2 equiv), pyridinium *p*-toluenesulfonate (5 mol%), CH₂Cl₂, r.t., 3.3 d; g) benzaldehyde dimethylacetal (1.1 equiv), PTSA (5 mol%), CH₂Cl₂, r.t., 22 h; h) Bu₄NF·3H₂O (3.6 equiv), THF, r.t., 6 h; i) Et₃N (8 equiv), Me₃SiCI (4 equiv), CH₂Cl₂, 0 °C, 3 h; j) Na₂CO₃ (0.8 equiv), trifluoroacetic anhydride (as a solvent), 0 °C, 10 min.

The C^{α}–O bond of α , β -dihydroxyketone αS , βR -10**a** was cleaved by treatment with SmI₂¹⁶ in THF–MeOH at –78 °C (50 min) to room temperature (30 min) furnishing β -hydroxyketone **11a** in 52% yield (Scheme 2, top row). It is plausible that this transformation entails the following steps: electron transfer (giving the ketyl), C^{α}–O bond rupture, electron transfer (giving the α -desoxygenated eno-

Synlett 2005, No. 19, 2905–2910 $\,$ © Thieme Stuttgart \cdot New York

late), and proton transfer from the cosolvent before the $E1_{cb}$ elimination of β -OH occurs.¹⁷ Prior to the present study, reductive C-O bond cleavages in O=C-C-O-containing compounds have rarely concerned C^{α} -OH groups: The only previously described defunctionalization of a simple a-hydroxyketone with SmI2 in THF-MeOH proceeded with only 29% yield at -78 °C;¹⁸ two related substrates could be defunctionalized by SmI₂ only in the presence of HMPA.^{19,20} Activated – i. e., β , γ -unsaturated - α -hydroxyketones were defunctionalized by SmI₂ in pure THF²¹ or in the presence either of HMPA.²¹ or a proton source.²² Apart from that, SmI₂-mediated C–O bond cleavage affected α -(sulfonyloxy)ketones,¹⁸ α , β -epoxy-ketones,²³ α -(acyloxy)ketones,^{18,24} α -(trialkylsiloxy)ketones, 18,21 and α -methoxyketones. 25 Conceptually related yet mechanistically distinct are the α -desoxygenations of α,β -epoxyketones and α,β -thiocarbonatoketones with Na⁺PhSeB(OEt)₃⁻²⁶ and Bu₃SnH,²⁷ respectively.

In an effort to enhance the efficiency of the defunctionalization $\alpha S.\beta R-10a \rightarrow 11a$, we protected the OH groups of dihydroxyketone αS , βR -10a as derivatives αS , βR -12a–17 (Scheme 2). Each of them plus SmI₂/THF/MeOH gave the desired β -hydroxyketone **11a**, too. The best-yielding SmI₂-mediated reductions started from bis(trimethylsilylether) 17 (\rightarrow 71% 18), acetonide $\alpha S, \beta R$ -12a (\rightarrow 65%) 11 a^{28}), or phenyl boronate 13 (\rightarrow 64%). Orthoformiate 15 provided 46% of 11a, sulfinate 14 22%, and benzylidene acetal 16 just 12%. While bis(trifluoroacetate) 19 reacted rapidly with SmI₂ it gave none of the desired trifluoroacetate 20. A fluorine-free diester analogue of diester 19 was not investigated. This was because optimally the reduction of such an ester would furnish a β -(acyloxy)ketone. The latter, from our experience, would be difficult to hydrolyze $(\rightarrow 11a)$ because of competing reversal to compound **9a** through β -elimination of HOAc.



Scheme 3 Synthesis of enantiomerically pure 1,3-diols 21. *Reagents and conditions*: a) BEt_3 (1.1 equiv), THF–MeOH 4:1 (v:v), r.t., 1 h; then -78 °C, addition of **11a** in THF, 2 h; NaBH₄ (0.8 equiv), 16 h; 90% of the pure diastereomer; b) $Me_4NBH(OAc)_3$ (4.05 equiv), MeCN–AcOH 1:1 (v:v), r.t., 30 min; then -40 °C, addition of **11a** in MeCN, 1 h; then -20 °C, 14 h; 51% of the pure diastereomer.

We terminated our exploratory sequence by reducing β -hydroxyketone **11a** diastereoselectively (Scheme 3). The reliability of this step is a pre-requisite for using β -hydroxyketones as latent *syn*- and *anti*-1,3-diol motifs in synthesis. Among *syn*-selective β -hydroxyketone reductions^{29–33} the unquestioned favorite is the Narasaka–Prasad procedure.²⁹ It relies on chelate formation with in situ formed diethylborinate followed by hydride delivery from NaBH₄ at –78 °C, furnishing diol diastereomer *syn*-**21** in 90% yield (after purification by flash chromatography¹¹). From several *anti*-selective β -hydroxyketone reductions^{34–39} we used Evans' OH-directed

hydride delivery³⁴ for accessing diol diastereomer *anti*-**21** (51% yield, again after flash chromatography¹¹).



Scheme 4 Asymmetric dihydroxylations of α,β-unsaturated ketones; reductive cleavage of the derived α ,β-dihydroxyketone acetonides. *Reagents and conditions*: a) K₂OsO₂(OH)₄ (1 mol%), (DHQ)₂PHAL (5 mol%), K₃Fe(CN)₆ (3.0 equiv), NaHCO₃ (3.0 equiv), K₂CO₃ (3.0 equiv), MeSO₂NH₂ (0.0 or 1.0 equiv*), *t*-BuOH-H₂O 1:1 (v:v), 0 °C; b) same* as (a) but using (DHQD)₂PHAL (5 mol%); c) PTSA (3 mol%), 2,2-dimethoxypropane (as a solvent), r.t.; d) SmI₂ (2.1–4.5 equiv), THF, –78 °C; addition of **12a–g** in THF-MeOH 2:1 (v:v) during 20 min; another 15 min at –78 °C; –78 °C to r.t. within 30 min; *MeSO₂NH₂ was only employed in the preparations of dihydroxyketones *αR*,*βS***-10a**, *αR*,*βS***-10c**, *αS*,*βR***-10c**, and *αR*,*βS***-10d**. For details, see Table 1.

Scheme 4 and Table 1 show that the AD of enone **9a** with $(DHQ)_2PHAL$ instead of $(DHQD)_2PHAL$ as the chiral auxiliary exhibits 99% ee vs. 100% ee in the latter case. The AD of several other enones **9b–g** proceeds with considerable enantiocontrol, too. Acetonide formation from the dihydroxyketone enantiomers $\alpha S, \beta R$ -**10a–g** only – because of their slightly superior enantiomeric purities – gave acetonides **12a–f** in high yields (94–100%) and somewhat less of the most volatile acetonide **12g** (81%). Combining these acetonides with 2.1–4.5 equivalents of SmI₂ in THF–MeOH and raising the temperature from –78 °C to ambient led to the desired defunctionalizations with the sole exception of compound **12f**: β -hydroxy-ketones **11a–e** and **g** were isolated with an average yield of 62%.

Table 1



Scheme 5 Synthesis of protected, enantiomerically pure 1,3,5-triols **25.** Reagents and conditions: a) $K_2OsO_2(OH)_4$ (1 mol%), (DHQD)₂PHAL (5 mol%), K₃Fe(CN)₆ (3.0 equiv), NaHCO₃ (3.0 equiv), K₂CO₃ (3.0 equiv), MeSO₂NH₂ (1.0 equiv), t-BuOH-H₂O 1:1 (v:v), 0 °C, 24 h; 90% [in a 74:26 mixture (w:w) with MeSO₂NH₂ which co-chromatographed with 23; an analytically pure sample of 23 was obtained following the same procedure but in the absence of MeSO₂NH₂; however, the yield there was only 60%]; b) pyridinium p-toluenesulfonate (10 mol%), 2,2-dimethoxypropane (36 equiv), no additional solvent, r.t., 12 h; 82%; c) SmI2 (3.0 equiv, prepared in situ), THF-MeOH 9:1 (v:v), -78 °C to r.t., 40 min; 90%; d) (i) BEt₃ (1.1 equiv), NaBH₄ (0.8 equiv), THF-MeOH 4:1 (v:v), -78 °C, 12 h; (ii) camphor sulfonic acid (10 mol%), CH₂Cl₂, r.t., 12 h; 91% over the 2 steps; e) (i) Me₄NBH(OAc)₃ (4.1 equiv), MeCN-AcOH 1:1 (v:v), -40 °C to -20 °C, 14 h; (ii) camphor sulfonic acid (10 mol%), CH₂Cl₂, r.t., 12 h; 94% over the 2 steps.

As demonstrated in Scheme 5, our sequence (1) enone formation, (2) AD, (3) C^{α}–O bond cleavage, (4) hydride addition strategy is applicable in a structurally more complex environment without difficulty. Enone **22** was dihydroxylated by a modified AD mix- β TM in 90% yield and with complete diastereoselectivity. Transformation of the

Compd 9–12	R ¹	R ²	Yield of α <i>R</i> ,β <i>S</i> -10 (%)	ee of α <i>R</i> ,β <i>S</i> - 10 (%) ^a	Yield of α <i>S</i> ,β <i>R</i> - 10 (%)	ee of α <i>R</i> ,β <i>S</i> - 10 (%) ^a	Yield of 11 (%)	Yield of $\alpha S, \beta R-12$ (%)
a	Bu	Me	100	99	89	100	65	94
b	Ph	Me	72	97	77	98	44	100
c	<i>i</i> -Pr	Me	87	98	91	99	68	93
d	Pr	Me	100	98	95	99	59	94
e	Pr	Bu	93	-	82	_	71	95
f	Pr	Ph	93	91	89	87	6	95
g	Pr	<i>i</i> -Pr	83	94	60	98	66	81

^a The ee values of compounds **10a**,c,d,g were determined by GLC, the ee of **10b** by GLC of the corresponding bis(trifluoroacetate), and the ee of **10f** by HPLC. No enantiomer separation was accomplished in the case of compound **10e**.

resulting dihydroxyketone **23** into acetonide **25** (82%) set the stage for reductive cleavage by SmI₂–THF–MeOH. This afforded the ester-containing β -hydroxyketone **24**⁴⁰ in 90% yield. Narasaka–Prasad reduction²⁹ provided a *syn*-diol. Its acid-catalyzed lactonization led to the protected 1,3,5-triol^{1,3}*anti*,^{3,5}*syn*-**26** (91% yield, 100% stereocontrol). The triacetoxyborohydride reduction³⁴ of β hydroxyketone **24** proceeded with complementary stereocontrol. After treatment of the resulting dihydroxyester with camphor sulfonic acid the ^{1,3}*anti*,^{3,5}*anti* isomer of the protected 1,3,5-triol **26** was isolated (94% yield, 91:9 mixture with diastereomer^{1,3}*anti*,^{3,5}*syn*-**26**).

In conclusion we have established a straightforward synthesis of 1,3-diols with completely controlled stereostructure. The β -hydroxyketones obtained from the α , β dihydroxyketone intermediates and stoichiometric to overstoichiometric amounts of SmI₂ (Scheme 2, Scheme 3, Scheme 4) should be susceptible to over-reduction by an excess of this reductant. Since such an overreduction is conceivably diastereoselective,³⁸ it appears as if one might realize a one-pot synthesis of stereopure 1,3diols from enantiomerically pure α , β -dihydroxyketones, \geq 4 equivalents of SmI₂, THF, and a proton source like methanol or water. Studies towards this end are underway in our laboratory.

Acknowledgment

We are indebted to the Fonds der Chemischen Industrie for supporting K.K. by a Kekulé fellowship and to Prof. Serge Neunlist (Ecole Nationale Supérieure de Chimie de Mulhouse) for making possible P.R.'s stage in Freiburg.

References

- Reviews: (a) Omura, S.; Tanaka, H. In Macrolide Antibiotics: Chemistry, Biology and Practice; Omura, S., Ed.; Academic Press Inc.: New York, **1984**, 351. (b) Beau, J. M. In Recent Progress in the Chemical Synthesis of Antibiotics; Lukacs, G.; Ohno, M., Eds.; Springer Verlag: Berlin, **1990**, 132. (c) Rychnovsky, S. D. Chem. Rev. **1995**, 95, 2021. (d) Schneider, C. In Organic Synthesis Highlights IV; Schmalz, H.-G., Ed.; Wiley-VCH: Weinheim, **2000**, 58.
- (2) Leading references: (a) RK-397: Denmark, S. E.; Fujimori, S. J. Am. Chem. Soc. 2005, 127, 8971. (b) Nystatin, candidin polyol parts: Kadota, I.; Hu, Y.; Packard, G. K.; Rychnovsky, S. D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11992. (c) RK-397: Burova, S. A.; McDonald, F. E. J. Am. Chem. Soc. 2004, 126, 2495. (d) Roxaticin: Evans, D. A.; Connell, B. T. J. Am. Chem. Soc. 2003, 125, 10899.
 (e) RK-397 polyol part: Schneider, C.; Tolksdorf, V.; Rehfeuter, M. Synlett 2002, 2098. (f) Dermostatin A: Sinz, C. J.; Rychnovsky, S. D. Tetrahedron 2002, 58, 6561.
 (g) Roxaticin polyol part: Paterson, I.; Collett, L. A. Tetrahedron Lett. 2001, 42, 1187. (h) Mycoticin A: Dreher, S. D.; Leighton, J. L. J. Am. Chem. Soc. 2001, 123, 341.
- (3) See, for example: (a) Evans, D. A.; Fitch, D. M.; Smith, T. E.; Cee, V. J. *J. Am. Chem. Soc.* 2000, *122*, 10033.
 (b) Paterson, I.; Florence, G. J.; Gerlach, K.; Scott, J. P.; Sereinig, N. *J. Am. Chem. Soc.* 2001, *123*, 9535.
- (4) 'Complex Mukaiyama aldol addition' giving an unbranched dihydroxyaldol: Rychnovsky, S. D.; Crossrow, J. Org. Lett. 2003, 5, 2367.

Synlett 2005, No. 19, 2905–2910 © Thieme Stuttgart · New York

- (5) See, for example: (a) Lipshutz, B. H.; Moretti, R.; Crow, R. *Tetrahedron Lett.* **1989**, *30*, 15. (b) Mori, Y.; Kohchi, Y.; Suzuki, M. J. Org. Chem. **1991**, *56*, 631. (c) Evans, D. A.; Gauchet-Prunet, J. A.; Carreira, E. M.; Charette, A. B. J. Org. Chem. **1991**, *56*, 741. (d) Wang, Z.; Deschênes, D. J. Am. Chem. Soc. **1992**, *114*, 1090. (e) Menges, M.; Brückner, R. Liebigs Ann. **1995**, 365. (f) Allerheiligen, S.; Brückner, R. Liebigs Ann./Recl. **1997**, 1667.
- (6) Reviews: (a) Lohray, B. B. Tetrahedron: Asymmetry 1992, 3, 1317. (b) Johnson, R. A.; Sharpless, K. B. Asymmetric Catalysis in Organic Synthesis; Ojima, I., Ed.; VCH: New York, 1993, 227. (c) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483. (d) Poli, G.; Scolastico, C. Methoden der organischen Chemie (Houben-Weyl), 4th ed., Vol. E21e; Helmchen, G.; Hoffmann, R. W.; Mulzer, J.; Schaumann, E., Eds.; Thieme: Stuttgart, 1995, 4547. (e) Salvadori, P.; Pini, D.; Petri, A. Synlett 1999, 1181. (f) Johnson, R. A.; Sharpless, K. B. In Catalytic Asymmetric Synthesis, 2nd ed.; Ojima, I., Ed.; Wiley-VCH: New York, 2000, 357. (g) Bolm, C.; Hildebrand, J. P.; Muniz, K. In Catalytic Asymmetric Synthesis, 2nd ed.; Ojima, I., Ed.; Wiley-VCH: New York, 2000, 399.
- Blundell, P.; Ganguly, A. K.; Girijavallabhan, V. M. Synlett 1994, 263.
- (8) Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; Morikawa, K.; Wang, Z. M.; Xu, D.; Zhang, X.-L. *J. Org. Chem.* **1992**, *57*, 2768.
- (9) Compounds α*S*,β*R*-10a–g, α*R*,β*S*-10a–g, 11a–g, α*R*,β*S*-12c, 13, 15, 17, 18, *syn*-21, and *anti*-21 provided correct ¹H NMR spectra and combustion analyses. Compounds α*S*,β*R*-12a–g except c were too volatile for combustion analysis and intermediates 14, 16, and 19 deemed not worth it; these compounds were characterized by ¹H NMR and low-resolution mass spectra only.
- (10) (3S,4R)-3,4-Dihydroxy-2-octanone (αS,βR-10a). At 0 °C, trans-3-octen-2-one (1.20 g, 1.38 mL, 9.51 mmol) was added to a stirred mixture of K₂OsO₂(OH)₄ (35.0 mg, 0.095 mmol, 1.0 mol%), (DHQD)₂PHAL (370.0 mg, 0.475 mmol, 5.0 mol%), NaHCO₃ (2.40 g, 28.5 mmol, 3.0 equiv), K₂CO₃ (3.95 g, 28.5 mmol, 3.0 equiv), MeSO₂NH₂ (903 mg, 9.51 mmol, 1 equiv), and K₃Fe(CN)₆ (9.39 g, 28.5 mmol, 3.0 equiv) in t-BuOH (25 mL) and H₂O (25 mL). After stirring for 60 h sat. aq Na₂SO₃ (120 mL) was added. The mixture was warmed to r.t. and extracted with EtOAc (3×70 mL). The combined organic extracts were washed with brine (60 mL) and dried over MgSO₄. Removal of the solvent in vacuo and purification of the residue by flash chromatography on silica gel¹¹ (column filling 5 cm \times 20 cm, cyclohexane-EtOAc 1:2, 60 mL fractions) provided the title compound (fractions 5-8, 1.39 g, 89%) as a colorless oil. The ee was ≥99% according to chiral GC {CP-Chirasil-Dex CB 25 m \times 0.25 mm catalog number CP7502; from 60 °C/10 min at 5 °C/min to 170 °C/20 min; 80 kPa, $t_{\rm R}$ (major enantiomer) = 26.46 min; no compound eluted around $t_{\rm R} = 25.71$ min [which was the independently measured value of $t_{\rm R}$ (minor enantiomer)]}. ¹H NMR (500 MHz, TMS internal standard in CDCl₃): $\delta = 0.93$ (t, $J_{8,7} = 7.1$ Hz, 8-H₃), 1.34-1.42 (m, 7-H₂, 6-H¹), 1.44-1.50 (m, 6-H²), 1.66 (m_c, presumably interpretable as ddd, $J_{5,4} = J_{5,6-H(1)} = J_{5,6-H(2)} =$ 6.9 Hz, 5-H₂), superimposed partly by 1.73 (br s, 4-OH), 2.28 (s, 1-H₃), 3.70 (br s, 3-OH), 3.95 (td, $J_{4,5} = 6.9$ Hz, $J_{4,3} = 1.4$ Hz, 4-H), 4.08 (d, $J_{3,4} = 1.5$ Hz, 3-H). $[\alpha]_{\rm D}^{20} + 94.6$ (c 0.45, CHCl₃). IR (CDCl₃): 3575, 3465, 2960, 2935, 2875, 2860, 1715, 1465, 1460, 1385, 1360, 1235, 1130, 1090, 935, 910, 885 cm⁻¹. Anal. Calcd for C₈H₁₆O₃ (160.2): C, 59.97; H, 10.07. Found: C, 59.68; H, 10.09.

- (11) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. **1978**, 43, 2923.
- (12) Enantioselective AD of achiral α , β -unsaturated ketones: (a) Becker, H.; Soler, M. A.; Sharpless, K. B. Tetrahedron **1995**, *51*, 1345. (b) Takikawa, H.; Shimbo, K.-i.; Mori, K. Liebigs Ann./Recl. 1997, 821. (c) Yokoyama, Y.; Mori, K. Liebigs Ann./Recl. 1997, 849. (d) List, B.; Shabat, D.; Barbas, C. F. III; Lerner, R. A. Chem.-Eur. J. 1998, 4, 881. (e) Giner, J.-L. Tetrahedron Lett. 1998, 39, 2479. (f) Shabat, D.; List, B.; Lerner, R. A.; Barbas, C. F. III Tetrahedron Lett. 1999, 40, 1437. (g) Toshima, H.; Aramaki, H.; Ichihara, A. Tetrahedron Lett. 1999, 40, 3587. (h) Schuricht, U.; Endler, K.; Hennig, L.; Findeisen, M.; Welzel, P. J. Prakt. Chem. 2000, 342, 761. (i) Rieder, C.; Jaun, B.; Arigoni, D. Helv. Chim. Acta 2000, 83, 2504. (j) Naoki, Y.; Suzuki, T.; Shibasaki, M. J. Org. Chem. 2002, 67, 2556. (k) Cox, R. J.; de Andres-Gomez, A.; Godfrey, C. R. A. Org. Biomol. Chem. 2003, 1, 3173. (1) Kumar, D. N.; Rao, B. V. Tetrahedron Lett. 2004, 45, 2227.
- (13) Diastereoselective AD of γ-chiral α,β-unsaturated ketones:
 (a) Carreira, E. J.; DuBois, J. J. Am. Chem. Soc. 1995, 117, 8106. (b) Cid, M. B.; Pattenden, G. Synlett 1998, 540.
 (c) Ishiyama, H.; Takemura, T.; Tsuda, M.; Kobayashi, J.-i. J. Chem. Soc., Perkin Trans. 1 1999, 1163. (d) Ohi, K.; Nishiyama, S. Synlett 1999, 573. (e) Lee, D.-H.; Rho, M.-D. Tetrahedron Lett. 2000, 41, 2573.
- (14) Diastereoselective AD of δ- and β'-chiral α,β-unsaturated ketones: Nicolaou, K. C.; Li, Y.; Sugita, K.; Monenschein, H.; Guntupalli, P.; Mitchell, H. J.; Fylaktakidou, K. C.; Vourloulis, D.; Giannakakou, P.; O'Brate, A. *J. Am. Chem. Soc.* 2003, *125*, 15443.
- (15) Diastereoselective AD of β'-chiral α,β-unsaturated ketones:
 (a) Schuppan, J.; Ziemer, B.; Koert, U. *Tetrahedron Lett.* **2000**, 41, 621. (b) Trost, B. M.; Harrington, P. E. J. Am. *Chem. Soc.* **2004**, 126, 5028. (c) Trost, B. M.; Wrobelski, S. T.; Chisholm, J. D.; Harrington, P. E.; Jung, M. J. Am. Chem. Soc. **2005**, 127, 13589.
- (16) Review: Kagan, H. B. Tetrahedron 2003, 59, 10351.
- (17) Confer ref. 18a for a different rationalization.
- (18) (a) Molander, G. H.; Hahn, G. J. Org. Chem. 1986, 51, 1135. (b) Similarly an O^α–SiMe₂t-Bu bond was cleaved off a ketone by: Abad, A.; Agulló, C.; Arnó, M.; Cuñat, A. C.; García, M. T.; Zaragozá, R. J. J. Org. Chem. 1996, 61, 5916.
- (19) (a) Mori, Y.; Yaegashi, K.; Furukawa, H. J. Am. Chem. Soc. 1997, 119, 4557. (b) Mori, Y.; Yaegashi, K.; Furukawa, H. J. Org. Chem. 1998, 63, 6200. (c) Voight, E. A.; Seradj, H.; Roethle, P.; Burke, S. D. Org. Lett. 2004, 6, 4045.
- (20) In lactones, oxygen-containing α-substituents including OH groups can be removed by SmI₂ in THF–HMPA, too: Hanessian, S.; Girard, C.; Chiara, J. L. *Tetrahedron Lett.* **1992**, *33*, 573.
- (21) Holton, R. A.; Somoza, C.; Chai, K.-B. *Tetrahedron Lett.* 1994, *35*, 1665.
- (22) (a) Py, S.; Khuong-Huu, F. *Tetrahedron Lett.* **1995**, *36*, 1661. (b) Georg, G. I.; Cheruvallath, Z. S.; Vander Velde, D. G.; Himes, R. H. *Tetrahedron Lett.* **1995**, *36*, 1783. (c) Georg, G. I.; Harriman, G. C. B.; Datta, A.; Ali, S.; Cheruvallath, Z. S.; Vander Velde, D. G.; Himes, R. H. J. Org. Chem. **1998**, *63*, 8926.
- (23) Molander, G. H.; Hahn, G. J. Org. Chem. 1986, 51, 2596.
- (24) White, D. J.; Nolen, E. G. Jr.; Miller, C. H. J. Org. Chem. 1986, 51, 1150.
- (25) (a) Smith, A. B. III; Dunlap, N. K.; Sulikowski, G. A. *Tetrahedron Lett.* **1988**, *29*, 439. (b) Kim, D.; Min, J.; Ahn, S. K.; Lee, H. W.; Choi, N. S.; Moon, S. K. *Chem. Pharm. Bull.* **2004**, *52*, 447.

- (26) Hosaka, M.; Hayakawa, H.; Miyashita, M. J. Chem. Soc., Perkin Trans. 1 2000, 4227.
- (27) Rho, H.-S. Synth. Commun. 1997, 27, 3887.
- (28) (a) (**4***R*)-**4**-Hydroxy-2-octanone (11a).
- At -78 °C a solution of SmI2 (0.1 M in THF, 42 mL, 4.2 mmol, 2.1 equiv) was added dropwise to a stirred solution of acetonide αS , βR -12a (0.40 g, 2.0 mmol) in THF (12 mL) and MeOH (6 mL). After 15 min the reaction mixture was gradually warmed to r.t. (within 30 min) and aq HCl (1 M, 4.2 mL) was added. After evaporating volatile material in vacuo the residue was diluted with $H_2O\left(10\mbox{ mL}\right)$ and extracted with t-BuOMe (3×15 mL). The combined organic extracts were washed with sat. aq NaHCO3 (10 mL) and brine (8 mL) and dried over $MgSO_4$. Removal of the solvent in vacuo and purification of the residue by flash chromatography on silica gel¹¹ (column filling $1.5 \text{ cm} \times 15$ cm, cyclohexane-EtOAc 4:1, 4 mL fractions) afforded the title compound (fractions 20-39, 0.186 g, 65%) as a colorless oil. ¹H NMR (400 MHz, MHz, TMS internal standard in CDCl₃): $\delta = 0.91$ (t, $J_{8,7} = 7.1$ Hz, 8-H₃), 1.29– 1.54 (m, 5-H₂, 6-H₂, 7-H₂), 2.18 (s, 1-H₃), AB signal $(\delta_A = 2.53, \delta_B = 2.62, J_{AB} = 17.7$ Hz, A part in addition split by $J_{A,4} = 9.0$ Hz, B part in addition split by $J_{B,4} = 2.9$ Hz, 3-H₂), 2.94 (br s, 4-OH), 4.03 (m_c, 4-H). $[a]_D^{20}$ -31.50 (*c* 0.20, CHCl₃). IR (CDCl₃): $\delta = 3565$, 2960, 2935, 2875, 2860, 1705, 1470, 1460, 1415, 1385, 1365, 1315, 1275, 1165, 1060 cm⁻¹. Anal. Calcd for C₈H₁₆O₂ (144.2): C, 66.63; H, 11.18. Found: C, 66.74; H, 10.97. (b) Enantiomer S-11a was prepared by an organocatalytic aldol addition (86% ee, 12% yield). See: Tang, Z.; Jiang, F.; Yu, L.-T.; Cui, X.; Gong, L.-Z.; Mi, A.-Q.; Jiang, Y.-Z.; Wu, Y.-D. J. Am. Chem. Soc. 2003, 125, 5262.
- (29) Borinylated β-hydroxyketone and NaBH₄: (a) Narasaka, K.; Pai, F.-C. *Chem. Lett.* **1980**, 1415. (b) Narasaka, K.; Pai, F.-C. *Tetrahedron* **1984**, 40, 2233. (c) Chen, K.-M.; Hardtmann, G. E.; Prasad, K.; Repic, O.; Shapiro, M. J. *Tetrahedron Lett.* **1987**, 28, 155. (d) Chen, K.-M.; Gunderson, K. G.; Hardtmann, G. E.; Prasad, K.; Repic, O.; Shapiro, M. J. *Chem. Lett.* **1987**, 1923.
- (30) BCl₃-complexed β-hydroxyketone and tetraalkylammonium boronate: Sarko, C. S.; Collibee, S. E.; Knorr, A. R.; DiMare, M. J. Org. Chem. **1996**, *61*, 868.
- (31) Reduction with DIBAL-H: Kiyooka, S.; Kuroda, H.; Shimasaki, Y. *Tetrahedron Lett.* **1986**, *27*, 3009.
- (32) Reduction with catecholborane: Evans, D. A.; Hoveyda, A. H. J. Org. Chem. 1990, 55, 5190.
- (33) (a) Reduction with Zn(BH₄)₂: Kashihara, H.; Suemune, H.; Fujimoto, K.; Sakai, K. *Chem. Pharm. Bull.* **1989**, *37*, 2610; in Et₂O. (b) Dakin, L. A.; Panek, J. S. *Org. Lett.* **2003**, *5*, 3995; in CH₂Cl₂.
- (34) Reduction with tetraalkylammonium triacetoxyborohydride: (a) Evans, D. A.; Chapman, K. T. *Tetrahedron Lett.* **1986**, 27, 5939. (b) Evans, D. A.; Chapman, K. T.; Carreira, E. M. *J. Am. Chem. Soc.* **1988**, *110*, 3560. (c) See also with sodium triacetoxyborohydride: Roeyeke, Y.; Keller, M.; Kluge, H.; Grabley, S.; Hammann, P. *Tetrahedron* **1991**, *47*, 3335.
- (35) Intramolecular hydrosilylation: (a) Anwar, S.; Davis, A. P. J. Chem. Soc., Chem. Commun. 1986, 831. (b) Anwar, S.; Davis, A. P. Tetrahedron 1988, 44, 3761.
- (36) (a) Reduction with SmI₂ and an aldehyde: Evans, D. A.; Hoveyda, A. H. *J. Am. Chem. Soc.* **1990**, *112*, 6447. Related Tishchenko reductions: (b) Schneider, C.; Klapa, K.; Hansch, M. Synlett **2005**, 91 and literature cited therein.
- (37) LiClO₄-complexed β-hydroxyketone and amine-complexed BH₃: Narayana, C.; Reddy, M. R.; Hair, M.; Kabalka, G. W. *Tetrahedron Lett.* **1997**, *38*, 7705.

Synlett 2005, No. 19, 2905-2910 © Thieme Stuttgart · New York

- (38) (a) Reduction with SmI₂: Keck, G. E.; Wager, C. A.; Sell, T.; Wager, T. T. *J. Org. Chem.* **1999**, *64*, 2172. (b) The diastereoselectivity of this reduction is sensitive to solvent variation: Chopade, P. R.; Davis, T. A.; Prasad, E.; Flowers, R. A. II Org. Lett. **2004**, *6*, 2685.
- (39) LiI-complexed β-hydroxyketone and LiAlH(Ot-Bu)₃: Ball,
 M.; Baron, A.; Bradshaw, B.; Omori, H.; MacCormick, S.;
 Thomas, E. J. *Tetrahedron Lett.* **2004**, *45*, 8737.
- (40) Methyl (6R)-7-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]-6hydroxy-4-oxoheptanoate (24). A suspension of 1,2-diiodoethane (2.062 g, 7.316 mmol, 3.0 equiv) and Sm powder 40 mesh (1.155 g, 7.316 mmol, 3.15 equiv) in THF (70 mL) was stirred at r.t. for 2 h. A deep-blue solution of SmI₂ was obtained. At -78 °C acetonide 25 (805 mg, 2.44 mmol) in THF-MeOH 2:1 (30 mL) was added within 10 min. After another 10 min, the mixture was warmed to r.t. and the reaction quenched 20 min later by the addition of aq HCl (1 M, 7.4 mL). The aqueous phase was separated and extracted with *t*-BuOMe (3×25 mL). The combined organic phases were washed successively with sat. aq NaHCO₃ (15 mL) and brine (12 mL) and dried over MgSO₄. Removal of the solvent in vacuo and purification of the residue by flash chromatography on silica gel¹¹ (column filling $3 \text{ cm} \times 20 \text{ cm}$, eluent = cyclohexane–EtOAc, 40:60)
- provided the title compound (fractions 8-24, 601 mg, 90%). ¹H NMR (500 MHz, CDCl₃): $\delta = 1.36$ and 1.41 [2 × s, 2'- $(CH_3)_2$], AB signal ($\delta_A = 1.69$, $\delta_B = 1.73$, $J_{AB} = 13.1$ Hz, in addition split by $J_{7-H(A),6} = 7.3 \text{ Hz}, * J_{7-H(A),4'} = 4.1 \text{ Hz}, * J_{7-H(B),4'} = 8.3 \text{ Hz}, ** J_{7-H(B),6} = 4.9 \text{ Hz}, ** 7-H_2$), presumably extreme AB signal where the 8 off-center signals are too small to be identified (so that J_{AB} cannot be extracted) so that the best description is: 2.61 (dd, $J_{3-H(1),2-H(1)} = 6.6$ Hz, $J_{3-H(1),2-H(2)} = 3.8$ Hz), 2.62 (dd, $J_{3-H(2),2-H(2)} = 6.6$ Hz,*** $J_{3-H(2),2-H(1)} = 2.7$ Hz,*** 3-H₂), 2.68 and 2.76 (2 × m_c, 2-H₂, 5-H₂), 3.26 (d, $J_{OH,6}$ = 3.5 Hz, 6-OH), 3.57 (dd, J_{gem} = $J_{5'-H(1),4'} = 7.8 \text{ Hz}, 5'-H^1$, 3.68 (s, 1-OCH₃), 4.09 (dd, $J_{gem} = 7.9 \text{ Hz}, J_{5'-\text{H}(2), 4'} = 6.1 \text{ Hz}, 5'-\text{H}^2), 4.25-4.33 \text{ (m, 6-H,}$ 4'-H); *, **, *** coupling constants exchangeable. ¹³C NMR [75 MHz, CDCl₃; APT spectrum, peak orientation 'up' ('+') for CH_3 and CH and 'down' ('–') for CH_2 and $C_{quat}];$ δ = '+' 25.67 and '+' 26.91 [2'-(CH₃)₂], '-' 27.55 (C-2), '-' 37.80 (C-3), '-' 39.94 (C-7), '-' 49.66 (C-5), '+' 51.88 (1-OCH₃), (c - 3), (c - 7), (-22.6 (c 1.92, CHCl₃). IR (film): 3490, 3015, 2985, 2945, 1735, 1715, 1435, 1415, 1370, 1215, 1165, 1060, 990, 870, 855 cm $^{-1}\!\!\!$ Anal. Calcd for $C_{13}H_{22}O_6$ (274.3): C, 56.92; H, 8.08. Found: C, 57.12; H, 7.99.